Literature DB >> 26015975

Suppression of leaky expression of adenovirus genes by insertion of microRNA-targeted sequences in the replication-incompetent adenovirus vector genome.

Kahori Shimizu1, Fuminori Sakurai2, Kyoko Tomita1, Yasuhito Nagamoto3, Shin-Ichiro Nakamura4, Kazufumi Katayama1, Masashi Tachibana1, Kenji Kawabata5, Hiroyuki Mizuguchi6.   

Abstract

Leaky expression of adenovirus (Ad) genes occurs following transduction with a conventional replication-incompetent Ad vector, leading to an induction of cellular immunity against Ad proteins and Ad protein-induced toxicity, especially in the late phase following administration. To suppress the leaky expression of Ad genes, we developed novel Ad vectors by incorporating four tandem copies of sequences with perfect complementarity to miR-122a or miR-142-3p into the 3'-untranslated region (UTR) of the E2A, E4, or pIX gene, which were mainly expressed from the Ad vector genome after transduction. These Ad vectors easily grew to high titers comparable to those of a conventional Ad vector in conventional 293 cells. The leaky expression of these Ad genes in mouse organs was significantly suppressed by 2- to 100-fold, compared with a conventional Ad vector, by insertion of the miRNA-targeted sequences. Notably, the Ad vector carrying the miR-122a-targeted sequences into the 3'-UTR of the E4 gene expressed higher and longer-term transgene expression and more than 20-fold lower levels of all the Ad early and late genes examined in the liver than a conventional Ad vector. miR-122a-mediated suppression of the E4 gene expression in the liver significantly reduced the hepatotoxicity which an Ad vector causes via both adaptive and non-adaptive immune responses.

Entities:  

Year:  2014        PMID: 26015975      PMCID: PMC4362365          DOI: 10.1038/mtm.2014.35

Source DB:  PubMed          Journal:  Mol Ther Methods Clin Dev        ISSN: 2329-0501            Impact factor:   6.698


  52 in total

1.  E4ORF3 requirement for achieving long-term transgene expression from the cytomegalovirus promoter in adenovirus vectors.

Authors:  D Armentano; M P Smith; C C Sookdeo; J Zabner; M A Perricone; J A St George; S C Wadsworth; R J Gregory
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

2.  Molecular regulation and biological function of adenovirus early genes: the E4 ORFs.

Authors:  B Täuber; T Dobner
Journal:  Gene       Date:  2001-10-31       Impact factor: 3.688

3.  A simplified system for constructing recombinant adenoviral vectors containing heterologous peptides in the HI loop of their fiber knob.

Authors:  H Mizuguchi; N Koizumi; T Hosono; N Utoguchi; Y Watanabe; M A Kay; T Hayakawa
Journal:  Gene Ther       Date:  2001-05       Impact factor: 5.250

4.  Post-isolation inducible nitric oxide synthase gene expression due to collagenase buffer perfusion and characterization of the gene regulation in primary cultured murine hepatocytes.

Authors:  H Wang; X Gao; S Fukumoto; S Tademoto; K Sato; K Hirai
Journal:  J Biochem       Date:  1998-11       Impact factor: 3.387

5.  Development of a complementing cell line and a system for construction of adenovirus vectors with E1 and E2a deleted.

Authors:  H Zhou; W O'Neal; N Morral; A L Beaudet
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

6.  Insertion of CTCF-binding sites into a first-generation adenovirus vector reduces the innate inflammatory response and prolongs transgene expression.

Authors:  Jerome Schaack; Liping Qiao; Marcin P Walkiewicz; Martin Stonehouse; Daniel A Engel; Andres Vazquez-Torres; Steven K Nordeen; Jianhua Shao; John W Moorhead
Journal:  Virology       Date:  2011-01-26       Impact factor: 3.616

7.  Further reduction in adenovirus vector-mediated liver transduction without largely affecting transgene expression in target organ by exploiting microrna-mediated regulation and the Cre-loxP recombination system.

Authors:  David Bennett; Fuminori Sakurai; Kahori Shimizu; Hayato Matsui; Kyoko Tomita; Takayuki Suzuki; Kazufumi Katayama; Kenji Kawabata; Hiroyuki Mizuguchi
Journal:  Mol Pharm       Date:  2012-11-12       Impact factor: 4.939

Review 8.  Functions of the adenovirus E4 proteins and their impact on viral vectors.

Authors:  Matthew D Weitzman
Journal:  Front Biosci       Date:  2005-05-01

9.  Systemic delivery of an adenoviral vector encoding canine factor VIII results in short-term phenotypic correction, inhibitor development, and biphasic liver toxicity in hemophilia A dogs.

Authors:  A M Gallo-Penn; P S Shirley; J L Andrews; S Tinlin; S Webster; C Cameron; C Hough; C Notley; D Lillicrap; M Kaleko; S Connelly
Journal:  Blood       Date:  2001-01-01       Impact factor: 22.113

10.  Toxicity and adaptive immune response to intracellular transgenes delivered by helper-dependent vs. first generation adenoviral vectors.

Authors:  Asad Mian; Margaretha Guenther; Milton Finegold; Philip Ng; John Rodgers; Brendan Lee
Journal:  Mol Genet Metab       Date:  2004-12-29       Impact factor: 4.797

View more
  12 in total

1.  Evaluation of transduction properties of an adenovirus vector in neonatal mice.

Authors:  Shunsuke Iizuka; Fuminori Sakurai; Kahori Shimizu; Kazuo Ohashi; Shin-Ichiro Nakamura; Masashi Tachibana; Hiroyuki Mizuguchi
Journal:  Biomed Res Int       Date:  2015-05-13       Impact factor: 3.411

2.  Suppression of Oncolytic Adenovirus-Mediated Hepatotoxicity by Liver-Specific Inhibition of NF-κB.

Authors:  Mitsuhiro Machitani; Fuminori Sakurai; Keisaku Wakabayashi; Kosuke Nakatani; Masashi Tachibana; Nobuyuki Kato; Toshiyoshi Fujiwara; Hiroyuki Mizuguchi
Journal:  Mol Ther Oncolytics       Date:  2017-10-26       Impact factor: 7.200

3.  Neonatal Gene Therapy for Hemophilia B by a Novel Adenovirus Vector Showing Reduced Leaky Expression of Viral Genes.

Authors:  Shunsuke Iizuka; Fuminori Sakurai; Masashi Tachibana; Kazuo Ohashi; Hiroyuki Mizuguchi
Journal:  Mol Ther Methods Clin Dev       Date:  2017-07-08       Impact factor: 6.698

4.  A MicroRNA124 Target Sequence Restores Astrocyte Specificity of gfaABC1D-Driven Transgene Expression in AAV-Mediated Gene Transfer.

Authors:  Grit Taschenberger; Julia Tereshchenko; Sebastian Kügler
Journal:  Mol Ther Nucleic Acids       Date:  2017-04-06       Impact factor: 8.886

Review 5.  Recent advances in genetic modification of adenovirus vectors for cancer treatment.

Authors:  Yuki Yamamoto; Masaki Nagasato; Teruhiko Yoshida; Kazunori Aoki
Journal:  Cancer Sci       Date:  2017-05-07       Impact factor: 6.716

6.  Antibodies against adenovirus fiber and penton base proteins inhibit adenovirus vector-mediated transduction in the liver following systemic administration.

Authors:  Kyoko Tomita; Fuminori Sakurai; Shunsuke Iizuka; Masahisa Hemmi; Keisaku Wakabayashi; Mitsuhiro Machitani; Masashi Tachibana; Kazufumi Katayama; Haruhiko Kamada; Hiroyuki Mizuguchi
Journal:  Sci Rep       Date:  2018-08-17       Impact factor: 4.379

7.  Adenovirus vector-mediated macrophage erythroblast attacher (MAEA) overexpression in primary mouse hepatocytes attenuates hepatic gluconeogenesis.

Authors:  Kahori Shimizu; Minako Okamoto; Tomoyuki Terada; Fuminori Sakurai; Hiroyuki Mizuguchi; Koji Tomita; Toru Nishinaka
Journal:  Biochem Biophys Rep       Date:  2017-04-20

Review 8.  Gene Therapy Leaves a Vicious Cycle.

Authors:  Reena Goswami; Gayatri Subramanian; Liliya Silayeva; Isabelle Newkirk; Deborah Doctor; Karan Chawla; Saurabh Chattopadhyay; Dhyan Chandra; Nageswararao Chilukuri; Venkaiah Betapudi
Journal:  Front Oncol       Date:  2019-04-24       Impact factor: 6.244

9.  NF-κB promotes leaky expression of adenovirus genes in a replication-incompetent adenovirus vector.

Authors:  M Machitani; F Sakurai; K Wakabayashi; K Nakatani; K Shimizu; M Tachibana; H Mizuguchi
Journal:  Sci Rep       Date:  2016-01-27       Impact factor: 4.379

10.  A 'poly-transfection' method for rapid, one-pot characterization and optimization of genetic systems.

Authors:  Jeremy J Gam; Breanna DiAndreth; Ross D Jones; Jin Huh; Ron Weiss
Journal:  Nucleic Acids Res       Date:  2019-10-10       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.